Course of quality of life in short- and long-term survivors after radiotherapy for bone metastases
Patients with bone metastases, referred for radiotherapy, represent a highly heterogeneous group. One third survives more than two years with QoL scores comparable to, or somewhat lower than the Dutch reference population. An individualized treatment approach is needed, addressing both short-term symptom palliation and, if applicable, long-term goals.
Authors
- Joanne M. van der Velden
- Anouk van Oss
- Yvette M. van der Linden (ORCID: https://orcid.org/0000-0002-9003-6124)
- Renée Hovenier (ORCID: https://orcid.org/0009-0004-0858-7472)
- Jorrit‐Jan Verlaan (ORCID: https://orcid.org/0000-0001-8105-6660)
- Wietse S.C. Eppinga (ORCID: https://orcid.org/0000-0003-3020-463X)
- N. Kasperts (ORCID: https://orcid.org/0000-0002-3780-5545)
- R. H. Kuijten
- Roxanne Gal (ORCID: https://orcid.org/0000-0001-7340-4581)
- Eline H. Huele
- Bart J. Pielkenrood (ORCID: https://orcid.org/0000-0003-4701-3311)
- Helena M. Verkooijen (ORCID: https://orcid.org/0000-0001-9480-1623)
- Bas B J Bindels
Institutions
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.radonc.2025.111284
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00